These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32678313)

  • 41. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.
    Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer; 2020 Aug; 126(16):3788-3799. PubMed ID: 32497272
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ginsenoside Rg3 attenuates the osimertinib resistance by reducing the stemness of non-small cell lung cancer cells.
    Tan Q; Lin S; Zeng Y; Yao M; Liu K; Yuan H; Liu C; Jiang G
    Environ Toxicol; 2020 Jun; 35(6):643-651. PubMed ID: 31916386
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
    Wilson C; Nicholes K; Bustos D; Lin E; Song Q; Stephan JP; Kirkpatrick DS; Settleman J
    Oncotarget; 2014 Sep; 5(17):7328-41. PubMed ID: 25193862
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
    Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Knockdown of TMEM45A overcomes multidrug resistance and epithelial-mesenchymal transition in human colorectal cancer cells through inhibition of TGF-β signalling pathway.
    Zhu M; Jiang B; Yan D; Wang X; Ge H; Sun Y
    Clin Exp Pharmacol Physiol; 2020 Mar; 47(3):503-516. PubMed ID: 31788833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
    Hsu CC; Liao BC; Liao WY; Markovets A; Stetson D; Thress K; Yang JC
    J Thorac Oncol; 2020 Jan; 15(1):50-61. PubMed ID: 31557536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition.
    Sha J; Bai Y; Ngo HX; Okui T; Kanno T
    Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
    Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of the HIF-1α and NF-κB loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells.
    Cheng ZX; Wang DW; Liu T; Liu WX; Xia WB; Xu J; Zhang YH; Qu YK; Guo LQ; Ding L; Hou J; Zhong ZH
    Oncol Rep; 2014 Apr; 31(4):1891-8. PubMed ID: 24535079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
    Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways.
    Romaniello D; Mazzeo L; Mancini M; Marrocco I; Noronha A; Kreitman M; Srivastava S; Ghosh S; Lindzen M; Salame TM; Onn A; Bar J; Yarden Y
    Clin Cancer Res; 2018 Nov; 24(22):5610-5621. PubMed ID: 29967248
    [No Abstract]   [Full Text] [Related]  

  • 52. Loss of BRMS1 promotes a mesenchymal phenotype through NF-κB-dependent regulation of Twist1.
    Liu Y; Mayo MW; Xiao A; Hall EH; Amin EB; Kadota K; Adusumilli PS; Jones DR
    Mol Cell Biol; 2015 Jan; 35(1):303-17. PubMed ID: 25368381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction.
    Han R; Hao S; Lu C; Zhang C; Lin C; Li L; Wang Y; Hu C; He Y
    Mol Oncol; 2020 Jun; 14(6):1152-1169. PubMed ID: 32239624
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
    Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.
    Tong M; Gao M; Xu Y; Fu L; Li Y; Bao X; Fu H; Quan H; Lou L
    Cancer Sci; 2019 Nov; 110(11):3584-3594. PubMed ID: 31446643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer.
    Suda K; Murakami I; Yu H; Kim J; Tan AC; Mizuuchi H; Rozeboom L; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    Mol Cancer Ther; 2018 Oct; 17(10):2257-2265. PubMed ID: 30049789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer.
    Li L; Wang Y; Jiao L; Lin C; Lu C; Zhang K; Hu C; Ye J; Zhang D; Wu H; Feng M; He Y
    Cancer Lett; 2019 Jun; 452():191-202. PubMed ID: 30910592
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro.
    Hsiao SH; Lu YJ; Li YQ; Huang YH; Hsieh CH; Wu CP
    Mol Pharm; 2016 Jun; 13(6):2117-25. PubMed ID: 27169328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.